CHIT1

CHIT1 (chitotriosidase-1) is a GH18-family chitinase secreted by activated macrophages and microglia that functions as a pro-inflammatory and profibrotic effector linking innate immune activation to tissue remodeling, neurodegeneration, and metabolic reprogramming. CHIT1 expression increases dramatically during monocyte-to-macrophage differentiation and is differentially regulated during M1 and M2 polarization (PMID:23149946); in disease-associated macrophage and microglial subpopulations, CHIT1 drives pulmonary fibrosis, granulomatous inflammation, and airway remodeling, as demonstrated by genetic knockout and pharmacological inhibition with OATD-01 (PMID:35122869, PMID:36199746, PMID:36902148). In the aging CNS, CHIT1-expressing microglia trigger motor neuron senescence through SMAD signaling activation (PMID:37907096), while in Alzheimer's disease models CHIT1 promotes an anti-inflammatory microglial phenotype and amyloid-β clearance via interaction with IDH1 through Ca²⁺-activated K⁺ channels (PMID:39829408). CHIT1 also regulates macrophage glycolytic metabolism and IL-1β secretion, and contributes to osteoclast-mediated bone resorption (PMID:26528182).

1. 2013 Medium

   Establishing CHIT1 as a differentiation-regulated macrophage product resolved the question of which cell states produce this chitinase, showing exponential upregulation during monocyte-to-macrophage transition with differential regulation during M1 versus M2 polarization.

   Evidence RT-PCR time-course in human monocyte-derived macrophages polarized with LPS/IFN-γ or IL-4

   PMID:23149946

   Open questions at the time

   • Transcription factor networks controlling CHIT1 induction not defined
   • Protein secretion kinetics not measured
   • Functional consequence of polarization-dependent regulation unknown
2. 2015 Medium

   Demonstrating that CHIT1 knockdown reduces bone resorption pit formation established a direct functional role for CHIT1 in osteoclast-mediated bone degradation beyond its use as a biomarker.

   Evidence siRNA knockdown in U266 myeloma cells with dentin disk resorption assay and CHIT1 enzyme activity measurement

   PMID:26528182

   Open questions at the time

   • Single cell line (U266) used — not validated in primary osteoclasts
   • Substrate specificity in bone matrix not characterized
   • Downstream signaling pathways in osteoclasts not identified
3. 2017 Medium

   Localizing CHIT1 to activated microglia and macrophages in ALS corticospinal tracts established CHIT1 as a CNS neuroinflammation marker and raised the question of whether it is functionally pathogenic or simply a bystander.

   Evidence Immunohistochemistry with IBA1/CD68 co-staining on postmortem ALS spinal cord tissue

   PMID:29142138

   Open questions at the time

   • No functional manipulation performed
   • CSF CHIT1 levels not correlated with tissue expression in same patients
   • Cell-autonomous versus paracrine effects unresolved
4. 2022 High

   Genetic and pharmacological inactivation of CHIT1 attenuating pulmonary fibrosis and granulomatous inflammation answered whether CHIT1 is a causal driver — not just a marker — of macrophage-mediated tissue remodeling.

   Evidence Chit1 KO and OATD-01 inhibition in bleomycin-induced fibrosis and granulomatous inflammation mouse models; ex vivo human BALF macrophage assays

   PMID:35122869 PMID:36199746

   Open questions at the time

   • Direct chitin substrate or endogenous ligand in mammalian lung not identified
   • Downstream signaling cascade linking CHIT1 to profibrotic gene expression not mapped
   • Whether enzymatic activity or a non-catalytic function drives fibrosis not distinguished
5. 2023 High

   Demonstrating that secreted CHIT1 from aged microglia triggers motor neuron senescence via SMAD signaling in NHP and human models resolved the functional question raised by ALS/aging biomarker studies, establishing a causal paracrine mechanism in neurodegeneration.

   Evidence snRNA-seq, in vivo NHP spinal cord CHIT1 protein injection, in vitro human motor neuron co-culture with SMAD pathway analysis

   PMID:37907096

   Open questions at the time

   • Specific SMAD isoforms and receptor complexes mediating the response not identified
   • Whether CHIT1 enzymatic activity is required for SMAD activation not tested
   • Reversibility of motor neuron senescence upon CHIT1 withdrawal unknown
6. 2023 High

   Showing that CHIT1 inhibition reduces IL-13, TGF-β1, and subepithelial fibrosis in chronic asthma extended its profibrotic role beyond the lung parenchyma to airway remodeling, broadening the therapeutic rationale for CHIT1 targeting.

   Evidence Chronic HDM murine asthma model with OATD-01 pharmacological inhibition, BAL cytokine measurement, and histological scoring

   PMID:36902148

   Open questions at the time

   • Mechanism connecting CHIT1 inhibition to reduced IL-13 not elucidated
   • Contribution of CHIT1 in epithelial versus macrophage compartment not separated
7. 2024 Medium

   Identifying CHIT1 in microglia transitioning to an activated lipid-metabolism-enriched state in MS lesions connected CHIT1 to lipid-laden phagocyte biology, suggesting a metabolic dimension beyond chitin degradation.

   Evidence scRNA-seq of CSF and CNS tissue from MS patients with neuropathological IHC validation

   PMID:38866782

   Open questions at the time

   • Functional manipulation in MS models not performed
   • Whether CHIT1 directly modulates lipid metabolism in microglia not tested
   • Relationship between CHIT1 and myelin debris processing unknown
8. 2024 Medium

   Demonstrating that CHIT1 inactivation inhibits macrophage glycolysis, alters central carbon metabolites, and suppresses IL-1β secretion established a metabolic regulatory function linking CHIT1 to immunometabolic reprogramming in MASH.

   Evidence (preprint) CHIT1 KO and OATD-01 in murine/rat MASH models with RNA-seq and metabolic flux assays in primary macrophages

   Open questions at the time

   • Preprint — not yet peer-reviewed
   • Mechanism by which a chitinase regulates glycolysis not identified
   • Whether metabolic effects are cell-autonomous or secondary to inflammatory milieu changes not resolved
9. 2025 Medium

   Identifying IDH1 as a CHIT1 interaction partner mediating anti-inflammatory microglial phenotype and Aβ clearance via Ca²⁺-activated K⁺ channels provided the first defined signaling axis through which CHIT1 exerts neuroprotective effects in Alzheimer's disease.

   Evidence CHIT1 overexpression in APP/PS1 mice, 4D label-free quantitative proteomics, patch clamp electrophysiology, IDH1 knockdown rescue in N9/BV-2/HT-22 cells

   PMID:39829408

   Open questions at the time

   • Single lab — IDH1 interaction awaits independent confirmation
   • Whether CHIT1 enzymatic activity is required for the IDH1-mediated axis not tested
   • Structural basis of CHIT1–IDH1 interaction not determined

• A central unresolved question is whether CHIT1's diverse disease-modulating effects require its chitinolytic enzymatic activity, a non-catalytic protein–protein interaction function, or both — and what endogenous substrate or ligand CHIT1 acts on in mammalian tissues lacking environmental chitin.
• Endogenous mammalian substrate or binding partner triggering CHIT1 effects unidentified
• Catalytic-dead mutant studies not reported
• Structural mechanism linking active-site occupation to downstream signaling not established in vivo